Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
APOKYN vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Apomorphine is a non-ergoline dopamine agonist that stimulates dopamine D2 and D1 receptors. It also activates D3, D4, and D5 receptors and has some serotonergic and adrenergic activity.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Treatment of acute, intermittent hypomobility episodes (off episodes) in patients with advanced Parkinson's disease
Mild to moderate pain,Fever
Subcutaneous injection: 0.2 m L (2 mg) as a test dose, then 0.1-0.6 m L (1-6 mg) as needed for episodes of hypomobility; maximum single dose: 0.6 m L (6 mg); maximum daily dose: 2.0 m L (20 mg).
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
Terminal elimination half-life approximately 30–60 minutes (range 0.5–1 hour); clinically, rapid clearance necessitates continuous or frequent dosing for sustained effect
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Primarily hepatic via N-demethylation to norapomorphine; also undergoes sulfation and glucuronidation. CYP enzymes involved include CYP2B6, CYP2C19, and CYP3A4.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Renal (approx. 90% as metabolites and unchanged drug; <5% unchanged in urine); biliary/fecal (minor, <10%)
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Approximately 99% bound to plasma proteins (primarily albumin)
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Approximately 1.5–2 L/kg (wide distribution, extensive tissue binding)
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Subcutaneous injection: approximately 100% (complete absorption); oral: negligible (<2%) due to extensive first-pass metabolism; intravenous: 100%
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
No specific dose adjustment recommended; use with caution in renal impairment. Data for GFR-based modifications are insufficient.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
No specific dose adjustment recommended; use with caution in moderate to severe hepatic impairment (Child-Pugh B or C).
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Not established; safety and efficacy in pediatric patients have not been studied.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
No specific dose adjustment; elderly patients may be more sensitive to adverse effects; initiate at low end of dosing range.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
None
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Cardiovascular effects: severe hypotension, syncope, bradycardia, and QT prolongation; monitor blood pressure and ECG,Nausea and vomiting: almost universal; pre-treatment with antiemetic (e.g., trimethobenzamide) required,Falling asleep during activities of daily living: risk of sudden sleep onset,Psychiatric effects: hallucinations, confusion, psychosis; may exacerbate existing disorders,Dyskinesias: may be precipitated or worsened,Impulse control disorders: compulsive behaviors reported,Hemolytic anemia: rare but severe risk; monitor blood counts,Skin reactions: injection site reactions, panniculitis, and pain
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Concurrent use of 5-HT3 antagonists (e.g., ondansetron, granisetron),Hypersensitivity to apomorphine or any component of the product,Concomitant use of drugs that prolong QT interval
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Avoid high-protein meals as they may delay absorption; take on an empty stomach for consistent response. No specific food contraindications.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Apomorphine is classified as Pregnancy Category C. In animal studies, maternal toxicity and fetal effects (reduced fetal weight, delayed ossification) were observed at doses ≥3 mg/kg/day (approximately 0.3 times the maximum recommended human dose). No adequate and well-controlled studies exist in pregnant women. For first trimester: potential risk based on animal data; second and third trimesters: unknown risk. Use only if potential benefit justifies potential risk to fetus.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
It is not known if apomorphine is excreted in human milk. No M/P ratio available. Due to potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account importance of drug to mother.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
No established dosing adjustments for pregnancy. Pharmacokinetic changes during pregnancy (increased volume of distribution, renal clearance) may reduce drug exposure; however, no dose adjustment guidelines are available. Individualize based on clinical response and tolerability.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Administer with an antiemetic (e.g., trimethobenzamide) to prevent severe nausea/vomiting. Use extreme caution in patients with prolonged QT interval. Injection sites must be rotated; do not inject into areas with bruising, redness, or hard lumps. Onset of effect is within 10 minutes but duration is short (about 1 hour). Monitor for orthostatic hypotension and dyskinesias.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take exactly as prescribed; do not use more often than directed.,Administer only into the abdomen, thigh, or upper arm; rotate injection sites.,Do not inject into areas with broken, bruised, or red skin.,Avoid driving or operating machinery until you know how the drug affects you.,Rise slowly from sitting or lying to reduce dizziness.,Report severe nausea, vomiting, hallucinations, or compulsive behaviors immediately.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about APOKYN vs ACEPHEN, answered by our medical review team.
APOKYN is a Dopamine Agonist that works by Apomorphine is a non-ergoline dopamine agonist that stimulates dopamine D2 and D1 receptors. It also activates D3, D4, and D5 receptors and has some serotonergic and adrenergic activity.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between APOKYN and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of APOKYN is: Subcutaneous injection: 0.2 m L (2 mg) as a test dose, then 0.1-0.6 m L (1-6 mg) as needed for episodes of hypomobility; maximum single dose: 0.6 m L (6 mg); maximum daily dose: 2.0 m L (20 mg).. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between APOKYN and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. APOKYN is classified as Category C. Apomorphine is classified as Pregnancy Category C. In animal studies, maternal toxicity and fetal effects (reduced fetal weight, delayed ossification) were observed at doses ≥3 mg/. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.